ILLUMINATE-B is now the seventh Phase 3 study of an RNAi therapeutic that has yielded positive results, and the first-ever study evaluating the safety and efficacy of this The post Alnylam reports positive results from ILLUMINATE-B phase 3 study of Lumasiran appeared first on Pharmaceutical Business review. … [Read more...]

Under the deal, CStone and Pfizer will involve in the development and commercialisation of CStone’s sugemalimab, an investigational anti-PD-L1 monoclonal antibody, in mainland China. They will also co-develop The post Pfizer to acquire minority stake in CStone Pharmaceuticals for $200m appeared first on Pharmaceutical Business review. … [Read more...]

Mesenchymal stem cells hold great promise to treat COVID-19 patients due to their potential in inhibiting the overactivated immune system and promoting the recovery of pulmonary and other The post Baylx receives US FDA clearance of Covid-19 IND application for umbilical cord tissue mesenchymal stem cells product appeared first on Pharmaceutical Business review. … [Read more...]

Earlier this year Infinity also received Fast Track designation for eganelisib in combination with the checkpoint inhibitor Opdivo® for the treatment of advanced urothelial cancer which the company The post Infinity receives fast track designation for eganelisib in combination with checkpoint inhibitor and chemotherapy for advanced TNBC appeared first on Pharmaceutical … [Read more...]

“This is an important day, as the initiation and dosing of the first patients in the ANCHOR phase 1 clinical study marks the first time that patients have The post Kuur Therapeutics announces first patients dosed with allogeneic CAR-NKT cell therapy appeared first on Pharmaceutical Business review. … [Read more...]